Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Enliven Therapeutics ( (ELVN) ).
On December 11, 2025, Enliven Therapeutics announced the appointment of Richard Fair as the new President and CEO, succeeding co-founder Sam Kintz, who will now serve as Head of Pipeline. This leadership change is part of Enliven’s strategy to advance the pivotal Phase 3 trial of ELVN-001 for chronic myeloid leukemia and its commercialization, reflecting the company’s commitment to its next phase of growth and enhancing its industry positioning.
The most recent analyst rating on (ELVN) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Enliven Therapeutics stock, see the ELVN Stock Forecast page.
Spark’s Take on ELVN Stock
According to Spark, TipRanks’ AI Analyst, ELVN is a Underperform.
Enliven Therapeutics’ stock is challenged by its early-stage financial profile with no revenue and ongoing losses. Despite strong liquidity, the reliance on external financing and lack of profitability weigh heavily. Technical indicators reinforce a cautious approach, as the stock shows bearish trends. Valuation metrics further reflect the typical risk profile of a biotech company in development.
To see Spark’s full report on ELVN stock, click here.
More about Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, focused on the discovery and development of small molecule therapeutics. The company aims to address unmet needs in precision oncology by improving survival and enhancing overall well-being through potentially first-in-class or best-in-class therapies.
Average Trading Volume: 581,220
Technical Sentiment Signal: Sell
Current Market Cap: $1.16B
See more data about ELVN stock on TipRanks’ Stock Analysis page.